OncoMatch/Clinical Trials/NCT07126782
The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT
Is NCT07126782 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Ex-vivo expanded allogeneic γδ T cells for aml (acute myelogenous leukemia).
Treatment: Ex-vivo expanded allogeneic γδ T cells — The purpose of this study is to evaluate the efficacy and safety of allogeneic γδ T cells in patients with MRD-positive AML after allo-HSCT.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: allogeneic hematopoietic stem cell transplant
AML patients receiving allo-HSCT
Lab requirements
Blood counts
adequate bone marrow reserve, defined as: absolute neutrophil count (ANC) > 0.5E9/L and platelet count ≥20E9/L
Kidney function
severe renal disorders excluded
Liver function
severe hepatic disorders excluded
Cardiac function
LVEF >45%, NYHA Class I/II, QTc ≤480 msec, no clinically significant arrhythmias requiring medication
Adequate bone marrow reserve, defined as: absolute neutrophil count (ANC) > 0.5E9/L and platelet count ≥20E9/L. Adequate organ function as per protocol. Cardiac abnormalities, meeting any of the following: Left ventricular ejection fraction (LVEF) ≤45%. NYHA Class III/IV congestive heart failure. QTc interval >480 msec. Other cardiac conditions considered unsuitable by the investigator. severe hepatic, renal, or metabolic disorders.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify